STOCK TITAN

Pharmala Biotech Holdings Inc. - $PMBHF STOCK NEWS

Welcome to our dedicated page for Pharmala Biotech Holdings news (Ticker: $PMBHF), a resource for investors and traders seeking the latest updates and insights on Pharmala Biotech Holdings stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Pharmala Biotech Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Pharmala Biotech Holdings's position in the market.

Rhea-AI Summary
PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: PMBHF) will present its intellectual property assets at the annual JPM healthcare conference in San Francisco. The company has received approval to move its PharmAla-1 (P1) molecule through the US Patent and Trademark Office Patent Prosecution Highway pathway. P-1, developed in partnership with the University of Windsor, has shown significant efficacy and pro-social effects at lower dosage levels than MDMA, with excellent safety pharmacology. PharmAla will share these developments with potential pharmaceutical industry partners at the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
none
-
News
Rhea-AI Summary
PharmAla Biotech Holdings Inc. qualifies for trading on the OTCQB Venture Market in the US and commences trading under the symbol 'PMBHF'. The OTC listing will provide greater access to its stock for US investors. PharmAla received regulatory allowances from the USFDA for its LaNeo MDMA for US Clinical Trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
Pharmala Biotech Holdings Inc.

OTC:PMBHF

PMBHF Rankings

PMBHF Stock Data

10.20M
5.34%
Biotechnology
Healthcare
Link
Canada
Vancouver